Candel Therapeutics, Inc.

CADL Nasdaq SEC CIK 1841387
Follow Candel Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$21.9M −94.1% vs same quarter last year
EPS, diluted −$0.28 −33.3% vs same quarter last year
Operating cash flow −$23.1M −125.9% vs same quarter last year
Operating income −$23M −74% vs same quarter last year
Net income by quarter
−$14.1M
$7.4M
−$4.8M
−$11.3M
−$29.5M
−$8.9M
−$38.9M
−$21.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$38.2M
FY24-−$55.2M
FY23-−$37.9M
FY22$125K−$18.8M
FY21$125K−$36.1M
FY20$125K−$17.7M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22−27777.6%−15035.2%
FY21−20580.8%−28899.2%
FY20−11048%−14144%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$38.9M
FY24−$27M
FY23−$34.7M
FY22−$32.7M
FY21−$24.1M
FY20−$10.5M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Candel Therapeutics
  • Healthcare median
−30000%−20000%−10000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearCandel TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22−15035.2%−80.4%
FY21−28899.2%−71.8%
FY20−14144%−62.2%
FY19-−46.2%